A Phase IIa, Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Presence of SENS-401 in the Perilymph After 7 Days of Repeated Oral Administration in Adult Participants Scheduled for Cochlear Implantation
Latest Information Update: 24 Sep 2024
At a glance
- Drugs Arazasetron (Primary)
- Indications Hearing loss; Sensorineural hearing loss
- Focus Proof of concept; Therapeutic Use
- Sponsors Sensorion
- 23 Sep 2024 According to a Sensorion media release, company reported the analysis of the final results during its symposium, held at the World Congress of Audiology, on September 20, 2024.
- 23 Sep 2024 Results presented in the Sensorian Media Release.
- 19 Sep 2024 According to a Sensorion media release, full data of this trial is anticipated to be presented at the World Congress of Audiology, on September 20, 2024